115 avenue Lacassagne
About AdociaAdocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.
Founders: Gérard Soula, Olivier Soula, and Rémi Soula
CEO: Gérard Soula
CFO: Valérie Danaguezian
Please click here for Adocia job opportunities.
Please click here for clinical trial information.
110 articles with Adocia
Adocia (Euronext Paris: FR0011184241 – ADOC), announced today the launch of a Phase 1 clinical study in collaboration with Dr. Ahmad Haidar, McGill University, Canada, to assess pharmacokinetic, glycemic control and safety of BioChaperone® Lispro Pramlintide (BC LisPram) prandial formulation in 16 people with type 1 diabetes compared to rapid insulin lispro.
ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81ˢᵗ Scientific Sessions
ADOCIA announced Adocia will have an oral presentation on the bi-hormonal treatment M1Pram at the 81st Scientific Sessions of the American Diabetes Association which will be held June 25-29, 2021, as a virtual event.
Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps
Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity treatment
ADOCIA (Euronext Paris: FR0011184241 – ADOC the “Company”and “Adocia”), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announced today its financial results, including revenue and cash position, for the quarter ended March 31st, 2020.
Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of approved proteins, announced its financial calendar for 2020.
Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides, announced third quarter revenue and net cash position as of September 30, 2019.
Establishment of a debt financing plan for a maximum amount of 15 million euros, with IPF Partners
Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case
The payment of USD 14.3 million corresponds to the USD 11.6 million in damages plus interest awarded to Adocia in August 2018 by an American Arbitration Association Panel presiding over Adocia’s arbitration claims against Eli Lilly
Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Adocia announced that it will deliver an oral presentation covering its ADO09 product at the 55th Annual Meeting of the European Association for the Study of Diabetes, being held September 16-20, 2019 in Barcelona, Spain.
Adocia Announces that the American Arbitration Association Tribunal Dismissed All Claims in Second Phase of Arbitration with Eli Lilly
Adocia announced that the American Arbitration Association Tribunal governing Adocia’s arbitration claims against Eli Lilly & Company dismissed both parties’ claims in the second and final phase of the arbitration between Adocia and Lilly.
Eli Lilly won an arbitration hearing over accusations the Indianapolis-based company misused confidential information regarding the intellectual property of its former business partner, France-based Adocia S.A.
The panel of three arbitrators ruled that Lilly acted appropriately regarding Adocia's intellectual property, and while they denied Lilly's smaller counterclaim, ruled that Lilly is not liable for damages.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes
Adocia announces the initiation of a Phase 1b study of ADO09, a ready-to-use, fixed ratio co-formulation of pramlintide, the only FDA-approved analog of amylin, and A21G human insulin analog, a rapid-acting insulin that is known to be the main circulating metabolite of insulin glargine.
ADOCIA announces its financial results, including revenue and cash position, for the quarter ended March 31st, 2019.
A turnover of €47.4 million, including €37.1 million related to the partnership signed with the Chinese company Tonghua Dongbao and €10.3 million following the judgment rendered in favor of Adocia in the first phase of the arbitration against Eli Lilly & Co
Adocia to Present New Clinical Data on BioChaperone® Technology at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
Adocia announced that four abstracts featuring its BioChaperone® technology have been accepted for presentation at the 12th International Conference on Advanced Technologies & Treatments for Diabetes being held February 20-23, 2019 in Berlin, Germany.
Adocia confirmed its financial calendar for 2019 with a change in date of the annual shareholder’s meeting.
Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas
ADOCIA announced today the first home-use trial to test Adocia’s BioChaperone® Lispro in Beta Bionics autonomous insulin delivery system, the iLetTM.
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of approved proteins, announced today its financial calendar for 2019.